A new oral medicine that is indicated for type 2 diabetics has gained positive reviews. Galvis is to be used in conjunction with the most common diabetic medications.
Novartis has received a positive opinion recommending European Union approval of Galvus® (vildagliptin) as a new once-daily oral medication for type 2 diabetes, a disease affecting an estimated 28 million patients in Europe
This approval came the same day that the CHMP recommended approval for two other Novartis medicines, Aclasta® (zoledronic acid 5 mg) for postmenopausal osteoporosis and Exelon® (rivastigmine transdermal patch) for Alzheimer’s disease. It was a good day for the …read more